The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cellular Therapy of Autoimmune Disease

Cellular Therapy of Autoimmune Disease

November 1, 2008 • By Alan Tyndall, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

To obtain cells for autologous HSCT before conditioning, stem cells are mobilized from the marrow to the peripheral blood, which permits stem-cell collection without general anesthesia or bone-marrow harvest. This mobilization is achieved by various protocols, many of which involve granulocyte colony-stimulating factor (G-CSF) or cyclophosphamide, a drug that is myelosuppressive and immunosuppressive per se but leads to a “rebound” mobilization of stem cells. The autologous hematopoetic stem cells are then collected through leukapheresis. In a further step, the hematopoetic stem cells expressing CD34+ as a stem-cell marker can be purified through positive selection using CD34 + sorting or negative selection of T or B cells using lineage-specific surface markers. This procedure leads to a more profound T cell depletion of the autograft (up to a CD3+ cell content lower than one T cell per 105 cells in the graft).

You Might Also Like
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
  • HSCT for Severe Autoimmune Diseases
Explore This Issue
November 2008
Table 1: Autoimmune Diseases in EBMT Register
click for large version
Table 1: Autoimmune Diseases in EBMT Register

Stem-cell mobilization is an immunosuppressive process, especially if cyclophosphamide is used. More profound immunosuppression is subsequently achieved through conditioning before HSCT. Conditioning means that an immunosuppressive regimen causes an at least transient bone marrow insufficiency, leading to a pancytopenia. The aim of conditioning is to eliminate to the greatest extent possible autoreactive cells, mostly T or B cells. The dose-limiting factor for such an intense immunosuppression is the hematotoxicity. However, hematotoxicity is reduced by retransfusion of autologous hematopoetic stem cells after conditioning. In any case, a transient pancytopenia occurs with a nadir around day 10 after HSCT. Transfusion of red cells or platelets may be necessary. Prophylactic antibiotic, antifungal, and antiviral therapy are given depending on the intensity of leuco- or lymphopenia. For conditioning chemotherapy, cyclophosphamide, busulfan or radiotherapy, or antibodies against components of the immune system have been used alone or in combination.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Allogeneic HSCT is associated with GvHD that carries significant morbidity and mortality. Theoretically, allogeneic HSCT offers the replacement of an autoreactive immune system with one that is putatively normal, but, in practice, this has yet to be proven. In fact, there are case reports of allogeneic HSCT being performed in patients with rheumatoid arthritis (RA) suffering from drug-induced aplastic anemia and, despite four years of remission, relapse occurred with all immune competent cells being of donor origin. On the other hand, similar cases have had up to 20 years clinical and serological remission.

Although hematopoetic reconstitution occurs within two weeks after HSCT, complete regeneration of the adaptive immune system, in contrast, is delayed up to years. It is thought that as the immune system returns in the presence of the inciting autoantigen, tolerance occurs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 9 | Single Page

Filed Under: Conditions, Guidelines Tagged With: Autoimmune disease, Cellular Therapy, Research, TreatmentIssue: November 2008

You Might Also Like:
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
  • HSCT for Severe Autoimmune Diseases
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.